AbbVie receives European approval for Humira to treat hidradenitis suppurativa

AbbVie has received approval from the European Commission (EC) for its Humira (adalimumab) to treat moderate-to-severe hidradenitis suppurativa (HS or acne inversa), which is a painful and chronic inflammatory skin disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news